A Phase 3 interventional study of Empagliflozin 25 MG in Peritoneal Dialysis Complication, End Stage Kidney Disease and Sodium-glucose Co-transporter-2 Inhibitors, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University Health Network, Toronto · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Kidney Failure, Chronic with a site in Canada — 20 open to participants now, 28 under way, 4 of them phase 3. Kidney Failure, Chronic · Canada.
Among the 134 studies in Kidney Failure, Chronic with a site in Canada, this one is the 93rd largest by planned enrollment of the 110 interventional ones that give a count, is one of 8 that started in 2024, is one of 23 in phase 3, reaches primary completion later than 14 of the 27 other live ones, and was the 117th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →20 of the 134 studies in Kidney Failure, Chronic with a site in Canada are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Bodyport Inc. · Sites in Canada, United States
Ages 21+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 45+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 21 · Phase 3 25 · Phase 4 11
First in 1996; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 79 across the 110 interventional studies, 109 across the 24 observational. Of the 91 that completed or were terminated, 17 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 134 have an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
University Health Network, Toronto has 8 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
9 of the studies in Kidney Failure, Chronic with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05715814Phase 3University Health Network, TorontomeChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis | 2027-05-01 |
| NCT02823821University of SydneyRandomised Evaluation of Sodium Dialysate Levels on Vascular Events | 2026-12 |
| NCT05968391Université de SherbrookeAcetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP) | 2026-12-15 |
| NCT04603014London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sInterdialytic Peritoneal UltraFiltration in HemoDialysis Patients | 2026-12-30 |
| NCT06032208London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sAn Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 134 studies in Kidney Failure, Chronic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).
The importance of RKF on the survival of patients on PD has been demonstrated in several observational studies. Despite this, there are limited pharmacological interventions available to slow the loss of RKF in these patients. There is an unmet need for novel cardiovascular and kidney protective strategies for patients on renal replacement therapies, including PD.
SGLT2 inhibitors have been shown to have both cardiovascular and kidney protective effects in individuals with kidney disease, with and without diabetes. These benefits have been attributed to diverse mechanisms and kidney benefits have been largely attributed to reductions in intraglomerular pressure at the single nephron level, reversibly lowering GFR in the short-term with long-term benefits. However, the beneficial effects of SGLT2 inhibitors have never been studied in patients on dialysis.
The CANARY study will provide insight into the safety and mechanisms of SGLT2 inhibitors in individuals on dialysis with RKF, with and without type 2 diabetes, over a period of 2 weeks. Demonstrating that protective mechanisms associated with SGLT2 inhibitors are intact in patients on PD with RKF would provide a strong rationale for a larger clinical trial to explore the use of these novel drugs in this unique clinical application. Additionally, our proposed study would provide timely mechanistic data to inform clinical decisions in the context of other large clinical trials such as EMPA-KIDNEY. These findings would help physicians make decisions on leaving patients on SGLT2 inhibitors even beyond end-stage kidney disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Empagliflozin 25 MG
PO once daily
Also known as: JARDIANCE
Change in measured GFR
GFR will be determined from the average of creatinine and urea clearance from a 24-hour urine collection.
Time frame: Before and 2 weeks after initiation of empagliflozin.
Rebound in GFR after Cessation of Therapy
A GFR measurement will be performed 2 weeks after cessation of empagliflozin, with the aim of capturing the reversible "rebound" in GFR after cessation of therapy.
Time frame: 2 weeks
Change in ultrafiltration volume
Time frame: 2 weeks
Change in fraction of glucose remaining in the dialysate
Time frame: 2 weeks
Change in dialysate/plasma creatinine
Time frame: 2 weeks
Change in dialysate/plasma urea
Time frame: 2 weeks
Change in sodium dialysate concentration
Time frame: 2 weeks
Change in glycated hemoglobin (HbA1c)
Time frame: 2 weeks
Change in systolic and diastolic blood pressure
Time frame: 2 weeks
Change in body weight
Time frame: 2 weeks
Change in body composition (percent body mass, body fat, and muscle mass)
Bioimpedence measurements will be taken to study the effects of intervention on body composition.
Time frame: 2 weeks
Change in fractional urine excretion of sodium
Urinary analysis will be performed to quantify the amount of sodium excretion.
Time frame: 2 weeks
Change in fractional urine excretion of glucose
Urinary analysis will be performed to quantify the amount of glucose excretion.
Time frame: 2 weeks
Change in eGFRβ2-microglobulin
Blood sample analysis to assess middle molecule clearance.
Time frame: 2 weeks
Change in degree of albuminuria
Urinary analysis will be performed to determine if there has been any change in the severity of albuminuria
Time frame: 2 weeks
Change in BNP (NT-proB-type Natriuretic Peptide)
Time frame: 2 weeks
Change in markers of neurohumoral activation, erythropoiesis, and inflammation.
Time frame: 2 weeks
The safety of empaglifllozin use in PD patients with RKF with regard to anuria (<100cc/day), volume depletion, diabetic ketoacidosis, genito-urinary infections, PD peritonitis and death will be evaluated.
Time frame: 2 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for May 2027, 32 months after the start.
Of 66 phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 48. This study's planned 32 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin
University Health Network, Toronto →